Glaukos Research and Development Expenses 2014-2025 | GKOS

Glaukos research and development expenses for the twelve months ending March 31, 2025 were $0.141B, a 6.95% decline year-over-year.

  • Glaukos annual research and development expenses for 2024 were $0.151B, a 4.79% increase from 2023.
  • Glaukos annual research and development expenses for 2023 were $0.144B, a 7.88% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.133B, a 31.95% increase from 2021.

Glaukos Research and Development Expenses 2014-2025 | GKOS

  • Glaukos annual research and development expenses for 2024 were $0.151B, a 4.79% increase from 2023.
  • Glaukos annual research and development expenses for 2023 were $0.144B, a 7.88% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.133B, a 31.95% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$183.7B
Thermo Fisher Scientific (TMO)$157.2B
Edwards Lifesciences (EW)$44.7B
Alcon (ALC)$42.9B
IDEXX Laboratories (IDXX)$41.9B
DexCom (DXCM)$33B
IQVIA Holdings (IQV)$27.4B
Mettler-Toledo (MTD)$24.6B
STERIS (STE)$22.4B
SONOVA HOLDING (SONVY)$17.3B
Waters (WAT)$17.2B
Hologic (HOLX)$14.2B
Sysmex ADR (SSMXY)$10.5B
Penumbra (PEN)$9.1B
Masimo (MASI)$8.6B
Globus Medical (GMED)$7.7B
Teleflex (TFX)$5B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3.8B
PROCEPT BioRobotics (PRCT)$3.2B
LivaNova (LIVN)$2.3B
Nihon Kohden (NHNKY)$2.2B
Veracyte (VCYT)$2B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.6B
Artivion (AORT)$1.3B
Paragon 28 (FNA)$1.1B
OPKO Health (OPK)$1.1B
Pulse Biosciences (PLSE)$1.1B
Tandem Diabetes Care (TNDM)$1B